Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others

Compass Pathways reported "successful" but underwhelming results for its Phase IIb clinical trial using psilocybin to treat Treatment Resistant Depression. We identify the winners and losers from this news.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.